Search clinical trials for: Methylnaltrexone bromide (Relistor®).

Total 138 results

Bausch Health Americas, Inc.

Withdrawn

A Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Pancreatic Cancer

United States
Bausch Health Americas, Inc.

Withdrawn

An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer

Pancreatic Cancer
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, Portugal, United Kingdom
Beth Israel Medical Center
Wyeth is now a wholly owned subsidiary of Pfizer

Withdrawn

Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?

Colonic Inertia
Karolinska University Hospital

Completed

Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients (MOVEMENT)

STEMI | Morphine | Ticagrelor | Methylnaltrexone

Sweden
University of Vermont

Completed

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

Neoplasms | Constipation | Opioid-Related Disorders

United States
Bausch Health Americas, Inc.
Pfizer

Completed

Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

Constipation

Canada, United States, Colombia, Korea, Republic of, Australia, Spain
University of Alabama at Birmingham

Recruiting

Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics

Chronic Widespread Pain

United States
University of Missouri-Columbia

Completed

Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation

Constipation Drug Induced

United States
St. John Health System, Michigan

Unknown

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit (MOVE-IT)

Opioid-induced Constipation

United States
Universitaire Ziekenhuizen KU Leuven

Completed

The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health

Endogenous and Esophageal Sensitivity
Bausch Health Americas, Inc.
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

Opioid-induced Constipation

United States
Bausch Health Americas, Inc.

Completed

Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

Healthy Adult Subjects

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Oral MOA-728 For The Treatment Of OIBD In Subjects With Chronic Non-Malignant Pain

Constipation

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation (OIC) in Subjects With Chronic Non-Malignant Pain

Constipation

United States
Region Örebro County
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Opioids and Esophageal Function

Pharyngeal Dysfunction | Esophageal Dysfunction

Sweden
AstraZeneca

Completed

A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany
M.D. Anderson Cancer Center

Recruiting

Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.

Head and Neck Squamous Cell Carcinoma

United States
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

Opioid-Induced Constipation

United States
Mayo Clinic
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

Gastric Motility Disorder

United States
University of Zurich

Completed

Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients (RELZH12)

Opioid Use, Unspecified With Other Opioid-induced Disorder

Switzerland
Bausch Health Americas, Inc.
Progenics Pharmaceuticals, Inc.

Completed

Study Evaluating Subcutaneous Methylnaltrexone For Treatment Of Opioid-Induced Constipation In Patients With Advanced Illness

Opioid-Induced Constipation

United States, Australia, Belgium, Canada, France, Germany, Italy, Mexico, United Kingdom, Brazil, Spain, Sweden
Alcon Research

Completed

Visual Function After Implantation of Bilateral AcrySoft ReSTOR Aspheric IOL

Cataract

United States
Sunovion Respiratory Development Inc.

Completed

Study to Investigate the Dose Response, Safety and Efficacy of Nebulized EP-101(SUN101) in Patients With Chronic Obstructive Pulmonary Disease (COPD): GOLDEN-1 Study

Chronic Obstructive Pulmonary Disease

United States, United Kingdom
Boehringer Ingelheim

Terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)

Pulmonary Disease, Chronic Obstructive

Switzerland
Alcon Research

Completed

ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens (IOL)

Cataract

United States
Alcon Research

Completed

Clinical Investigation of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)

Cataracts
Alcon Research

Completed

A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients

Cataracts
Alcon Research

Completed

Visual Outcomes After Cataract Surgery: Multifocal AcrySof® IQ ReSTOR® Intraocular Lenses Versus Monofocal Intraocular Lenses

Cataract
Boehringer Ingelheim

Completed

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Pulmonary Disease, Chronic Obstructive

Greece
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)

Neuromuscular Blockade
Boehringer Ingelheim

Completed

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Pulmonary Disease, Chronic Obstructive
Region Örebro County

Unknown

Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume

Pharyngeal Dysfunction | Pharyngeal Swallowing

Sweden
Merck Sharp & Dohme LLC

Completed

Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)

Anesthesia, General
Merck Sharp & Dohme LLC

Completed

Efficacy, Safety and Pharmacokinetics of Sugammadex (Org 25969; MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).

Neuromuscular Blockade
Chiesi Farmaceutici S.p.A.

Completed

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease (GLIMMER)

Chronic Obstructive Pulmonary Disease | COPD

United States
Alcon Research

Completed

AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (IOL) Model SN6AD2 [SV25T0] in Japan

Cataracts

Japan
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Alcon Research

Completed

A Comparison of Visual Function After Bilateral Implantation of Presbyopia-Correcting Intraocular Lenses (IOLs)

Cataract
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Glenmark Specialty S.A.

Completed

Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

United States
Thomas Schricker
Merck Sharp & Dohme LLC

Terminated

Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation With Moderate vs. Deep Neuromuscular Block

High-Frequency Jet Ventilation | Vocal Cord Resection

Canada
Alcon Research

Completed

Pilot Study of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)

Cataract
Merck Sharp & Dohme LLC

Completed

A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)

Gallbladder Disease

Germany, Italy
Merck Sharp & Dohme LLC

Completed

Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773)

Neuromuscular Blockade
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Alcon Research

Completed

AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL) Clinical Study in Japan

Cataracts

Japan

3

Subscribe